Single-stranded positive-sense RNA viruses account for a large number of clinically serious global pathogens and are the cause of many potentially life-threatening diseases: hepatitis C, dengue, yellow fever, ebola, zika, west nile, encephalitis viruses and coronaviruses, including SARS, MERS and SARS-CoV-2, the virus responsible for COVID-19.
The activity of a key viral enzyme, RNA-dependent RNA polymerase, also known as RNA polymerase, is required for replication and propagation of these viruses. The structure of this enzyme is highly conserved across RNA viruses. Most viral RNA polymerases have been identified on the basis of comparative sequence analysis, but it is important to know that viral genome replication is initiated by two different and distinct mechanisms.
Comprising more than 1,000 proprietary prodrugs of nucleoside and nucleotide analogs, Atea’s library of antiviral compounds has provided potent drug candidates that specifically target viral RNA polymerases. Based on extensive knowledge and years of experience discovering and developing antivirals, our team of scientists has designed drug candidates that include specific chemical modifications intended to enhance antiviral activity and maximize selectivity.
Unique prodrugs of nucleotide analogs are intrinsic to Atea’s innovative platform for developing safe, orally administered, direct-acting antiviral therapies.
AT-527 is the perfect example of the uniqueness of our platform in discovering highly innovative oral nucleotide therapeutics. This sophisticated double prodrug is synthesized as a specific salt form, which required new breakthroughs in our knowledge of medicinal chemistry and cellular pharmacology.
Atea is a clinical-stage biopharmaceutical company working to address unmet medical needs through novel antiviral treatment.
Copyright © 2020 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use